Cargando…

Efficacy and safety of lenalidomide for the treatment of acute myeloid leukemia: a systematic review and meta-analysis

BACKGROUND: Lenalidomide is effective for the treatment of low-risk myelodysplastic syndromes with deletion 5q abnormalities. However, whether lenalidomide leads to a significant improvement in treatment response and overall survival (OS) in cases of acute myeloid leukemia (AML) remains controversia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Chun-Hong, Wei, Min, Yang, Fei-Yan, Wu, Fu-Zhen, Chen, Lei, Wang, Jian-Kun, Liu, Qin, Huang, Jin-Xiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6152603/ https://www.ncbi.nlm.nih.gov/pubmed/30271212 http://dx.doi.org/10.2147/CMAR.S168610

Ejemplares similares

Safety and tolerability of lenalidomide maintenance in post-transplant acute myeloid leukemia and high-risk myelodysplastic syndrome
por: Pham, Brian, et al.
Publicado: (2021)

Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia
por: Kenealy, Melita, et al.
Publicado: (2019)

Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia
por: Medeiros, Bruno C., et al.
Publicado: (2018)

Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size
por: Berthon, Celine, et al.
Publicado: (2020)

Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis
por: He, Pin-Fang, et al.
Publicado: (2017)

Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia
por: Jain, Prachi, et al.
Publicado: (2017)

Lenalidomide Combined with Interferon α-1b and Interleukin-2 in the Treatment of 21 Cases of Acute Myeloid Leukemia
por: Cheng, Cheng, et al.
Publicado: (2021)

Lenalidomide and Chronic Lymphocytic Leukemia
por: González-Rodríguez, Ana Pilar, et al.
Publicado: (2013)

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
por: Alegre, Adrian, et al.
Publicado: (2011)

Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus
por: Cortés-Hernández, Josefina, et al.
Publicado: (2012)

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia
por: Roboz, Gail J., et al.
Publicado: (2017)

A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Liao, Dan, et al.
Publicado: (2019)

Lenalidomide in the Treatment of Chronic Lymphocytic Leukemia
por: Cortelezzi, Agostino, et al.
Publicado: (2012)

Favorable outcomes of DDX41‐mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine ± lenalidomide
por: Tiong, Ing S., et al.
Publicado: (2023)

Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial
por: Schroeder, Thomas, et al.
Publicado: (2023)

Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis
por: Chen, Xiu, et al.
Publicado: (2023)

Azacitidine and lenalidomide combination: a novel relapse prophylaxis regimen after allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia
por: Feng, Yimei, et al.
Publicado: (2023)

Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure
por: Alhuraiji, Ahmad, et al.
Publicado: (2017)

Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma
por: Patel, Krina K., et al.
Publicado: (2022)

Cyclosporine Broadens the Therapeutic Potential of Lenalidomide in Myeloid Malignancies
por: Dou, Aixia, et al.
Publicado: (2020)

Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis
por: Wu, Di, et al.
Publicado: (2017)

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
por: Platzbecker, U, et al.
Publicado: (2013)

Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia
por: Craddock, Charles, et al.
Publicado: (2019)

Efficacy and toxicity of cladribine for the treatment of refractory acute myeloid leukemia: a meta-analysis
por: Zhou, Anqi, et al.
Publicado: (2019)

Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials
por: Qiao, Shu-Kai, et al.
Publicado: (2015)

Efficacy and safety of lenalidomide in diffuse large B-cell lymphoma: a meta-analysis of randomized controlled trials
por: Liu, Jia, et al.
Publicado: (2022)

Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
por: Helbig, Grzegorz, et al.
Publicado: (2019)

Molecular testing for acute myeloid leukemia
por: Qin, Dahui
Publicado: (2022)

Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide
por: Negoro, Eiju, et al.
Publicado: (2016)

Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial
por: Hunault-Berger, M, et al.
Publicado: (2017)

Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort
por: Brune, Magdalena M., et al.
Publicado: (2021)

A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome
por: Saygin, Caner, et al.
Publicado: (2020)

“Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)”
por: Rasmussen, Bengt, et al.
Publicado: (2022)

A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells
por: Guinn, Barbara-ann, et al.
Publicado: (2023)

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
por: García-Gutiérrez, Valentín, et al.
Publicado: (2019)

Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis
por: Li, Jia, et al.
Publicado: (2021)

Clinical efficacy and safety of imatinib in the management of Ph(+) chronic myeloid or acute lymphoblastic leukemia in Chinese patients
por: Zhu, Yu, et al.
Publicado: (2014)

Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence
por: Stemer, Galia, et al.
Publicado: (2021)

Approaches to Managing Safety With Lenalidomide in Hematologic Malignancies
por: Blumel, Susan, et al.
Publicado: (2014)

Effect of Lenalidomide Maintenance in Chronic Lymphocytic Leukemia: A Meta-Analysis and Trial-Sequential Analysis
por: Yu, Tsung-Ying, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8bjgqc6tr53r116ttdk9455mi2